<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03257644</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 18424-102</org_study_id>
    <nct_id>NCT03257644</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis</brief_title>
  <official_title>An Open-Label, Pilot Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and the pharmacokinetics
      (PK) of topical ruxolitinib cream applied to pediatric subjects (age ≥ 2 to 17 years) with
      atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study has been modified to include younger pediatric subjects (age ≥2 to 11) in four
      additional cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 21, 2017</start_date>
  <completion_date type="Anticipated">September 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Screening through 30-37 days after end of treatment, up to approximately 12 weeks.</time_frame>
    <description>A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first application of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of ruxolitinib for Cohorts 1 and 2</measure>
    <time_frame>Day 1, Day 15, and Day 29</time_frame>
    <description>Venous blood samples will be collected to assess the PK of ruxolitinib .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of ruxolitinib for Cohorts 3, 4, 5 and 6</measure>
    <time_frame>Day 1, Day 10, and Day 29</time_frame>
    <description>Venous blood samples will be collected to assess the PK of ruxolitinib .</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib phosphate cream 0.5%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib phosphate cream 1.5%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib phosphate cream 0.75%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib phosphate cream 1.5%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib phosphate cream 0.75%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib phosphate cream 1.5%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib phosphate cream</intervention_name>
    <description>Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>INCB018424</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric subjects aged ≥ 2 to 17 years, inclusive

          -  Subjects diagnosed with AD as defined by the Hanifin and Rajka criteria.

          -  Subjects with active inflammation associated with AD.

          -  Subjects with an Investigator's Global Assessment (IGA) score of at least 2 at
             screening and baseline.

          -  Subjects with body surface area (BSA) of AD involvement of 8% to 20% at screening and
             baseline.

          -  Subjects who agree to discontinue all agents used to treat AD from screening through
             the final follow-up visit.

          -  Subjects of childbearing potential must agree to take appropriate precautions to avoid
             pregnancy or fathering a child for the duration of study participation.

          -  Written informed consent of the parent(s) or legal guardian and a verbal or written
             assent from the subject when possible.

        Exclusion Criteria:

          -  Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined
             by the investigator over the previous 4 weeks before baseline.

          -  Use of topical treatments for AD (other than bland moisturizer such as Eucerin® cream)
             within 2 weeks of baseline.

          -  Concurrent conditions and history of other diseases:

               -  Presence of AD lesions only on the hands or feet without a history of involvement
                  of other classical areas of involvement such as the face or the flexural folds.

               -  Other types of eczema.

               -  Any other concomitant skin disorder (eg, generalized erythroderma such as
                  Netherton Syndrome, or psoriasis), pigmentation, or extensive scarring that in
                  the opinion of the investigator may interfere with the evaluation of AD lesions
                  or compromise subject safety.

               -  Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome,
                  Wiskott-Aldrich syndrome) or have a history of malignant disease within 5 years
                  before the baseline visit.

               -  Chronic or acute infection requiring treatment with systemic antibiotics,
                  antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks before
                  the baseline visit.

               -  Active acute bacterial, fungal, or viral (eg, herpes simplex, herpes zoster,
                  chicken pox) skin infection within 1 week before the baseline visit.

               -  Chronic asthma requiring more than 880 μg of inhaled budesonide or equivalent
                  high dose of other inhaled corticosteroids.

          -  Subjects with cytopenias at screening per protocol-defined criteria.

          -  Use of the following medications:

               -  Systemic immunosuppressive or immunomodulating drugs (eg, oral or injectable
                  corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine)
                  within 4 weeks or 5 half-lives of baseline (whichever is longer).

               -  Subjects taking potent systemic cytochrome P450 3A4 inhibitors or fluconazole
                  within 2 weeks or 5 half lives, whichever is longer, before the baseline visit
                  (topical agents with limited systemic availability are permitted).

               -  Subjects who have previously received JAK inhibitors, systemic or topical (eg,
                  ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib).

               -  Current treatment or treatment within 30 days or 5 half-lives (whichever is
                  longer) before the baseline visit with another investigational medication or
                  current enrollment in another investigational drug protocol.

               -  Use of any prohibited medications within 14 days or 5 half-lives (whichever is
                  longer) of the baseline visit.

          -  Parent or legal guardian who, in the opinion of the investigator, is unable or
             unlikely to comply with the administration schedule and study evaluations or are
             unable or unwilling to apply the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kuligowski, MD, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cahaba Dermatology</name>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Sky Dermatology</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children'S Hospital Los Angeles Specialt</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children'S Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acevedo Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floridian Research Institute Llc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rm Medical Research Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iact Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clincal Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Fivenson, Md, Pllc</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates Llc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Association</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cyn3Rgy Research - Clinedge - Ppds</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 18, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Janus kinase (JAK) inhibitor</keyword>
  <keyword>pediatric</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

